BGM Group Ltd. BGM

Competitive advantage analysis · healthcare

Corporate Default
Overall moat score
37/100
Developing

Ranked against 90 peers in Drug Manufacturers - Specialty & Generic

About BGM Group Ltd.

BGM Group Ltd manufactures and distributes active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives (TCMD), and other by-products in China. The company provides licorice products, including Gan Di Xin, an antitussive and expectorant medicine; Qilian Shan Licorice Extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, a primary ingredient for medical preparation … Full BGM analysis →

Key strengths

  • Strong Interest Coverage & Conservative Leverage Debt serviceability is strong (score 0.77), with robust interest coverage.

Key risks

  • Scale Without Profitability Despite scale, profitability lags peers (score 0.19), suggesting limited competitive advantage.
  • Below-Peer Operating Efficiency Operating margin at 26.2th percentile indicates below-peer efficiency.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Developing
32
Premium

Signals, strengths and risks for Pricing Power

Premium

Signals, strengths and risks for Cost Advantage

Premium

Signals, strengths and risks for Customer Stickiness

Premium

Signals, strengths and risks for Capital Efficiency

Premium

Signals, strengths and risks for Resilience

Premium

Signals, strengths and risks for Scale & Market Position

Where BGM ranks in Drug Manufacturers - Specialty & Generic

BGM Group Ltd. ranks #53 of 91 scored companies in Drug Manufacturers - Specialty & Generic by moat score — the top 58%. The widest moat in the group is Zoetis Inc. (ZTS) at 85/100.

# Company Moat score Rating
49 Evolus, Inc. Common Stock EOLS 39/100 Developing
50 Regencell Bioscience Holdings L RGC 39/100 Developing
51 Sonoma Pharmaceuticals, Inc. SNOA 39/100 Developing
52 cbdMD, Inc. YCBD 39/100 Developing
53 BGM Group Ltd. BGM 37/100 Developing
54 Biofrontera Inc. BFRI 37/100 Developing
55 Biofrontera Inc. Warrants BFRIW 37/100 Developing
56 IM Cannabis Corp. IMCC 37/100 Developing
57 Alpha Teknova, Inc. TKNO 36/100 Developing

See every Pharma / Mature Biotech company ranked by moat score →

How BGM scores on the Corporate Default defenses

Pricing Power

Score 32 · 20% of the moat score

Pricing power is the ability to raise prices without losing volume.

Cost Advantage

Score 36 · 15% of the moat score

A cost advantage means delivering the same product for structurally less — better purchasing, denser distribution, a more automated process.

Customer Stickiness

Score 39 · 15% of the moat score

Stickiness is what makes revenue repeat without being re-won every year.

Capital Efficiency

Score 44 · 18% of the moat score

Capital efficiency asks what the company earns on the money tied up in the business.

Resilience

Score 54 · 17% of the moat score

Resilience is the capacity to get through a bad year on its own terms — enough liquidity, enough interest cover, and enough cash generation to avoid a rescue financing or a forced sale.

Scale & Market Position

Score 19 · 15% of the moat score

Scale matters only when it converts into economics.

How each Corporate Default defense is measured, in full →

Understanding BGM's moat

What is BGM Group Ltd.'s moat score?

BGM Group Ltd. (BGM) scores 37 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as developing. It ranks #53 of 91 scored companies in Drug Manufacturers - Specialty & Generic, the top 58%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 90 companies in Drug Manufacturers - Specialty & Generic. Its strongest defense is Resilience (54/100) and its weakest is Scale & Market Position (19/100).

How does BGM Group Ltd. compare with other Drug Manufacturers - Specialty & Generic companies?

BGM Group Ltd. ranks #53 of 91 scored companies in Drug Manufacturers - Specialty & Generic by moat score. The widest moat in Drug Manufacturers - Specialty & Generic is Zoetis Inc. (ZTS) at 85/100. The companies ranked closest are cbdMD, Inc. (YCBD) at 39 just above it and Biofrontera Inc. (BFRI) at 37 just below it.

How is the moat score calculated?

Each company is scored with an industry-specific template — Corporate Default in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 90 companies in Drug Manufacturers - Specialty & Generic. The defenses are then weighted to produce the overall score out of 100.

Why is BGM Group Ltd. scored with the Corporate Default template?

Most public companies sell a product or a service at a margin, so the moat question is whether that margin survives contact with competitors. The Corporate template scores the six defenses that show up in a general operating company's financial signature: whether it can hold price, produce more cheaply than rivals, keep its customers, earn a return above its cost of capital, withstand a downturn, and turn size into economics.

Which competitive defenses are measured for BGM Group Ltd.?

The Corporate Default template measures 6 defenses, and BGM scores: Pricing Power (32), Cost Advantage (36), Customer Stickiness (39), Capital Efficiency (44), Resilience (54), Scale & Market Position (19). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.

Send Feedback
Please select a category.
0/1000